W R Crom

1.3k total citations
23 papers, 1.0k citations indexed

About

W R Crom is a scholar working on Public Health, Environmental and Occupational Health, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, W R Crom has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Public Health, Environmental and Occupational Health, 7 papers in Molecular Biology and 7 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in W R Crom's work include Acute Lymphoblastic Leukemia research (13 papers), Cancer therapeutics and mechanisms (6 papers) and Acute Myeloid Leukemia Research (5 papers). W R Crom is often cited by papers focused on Acute Lymphoblastic Leukemia research (13 papers), Cancer therapeutics and mechanisms (6 papers) and Acute Myeloid Leukemia Research (5 papers). W R Crom collaborates with scholars based in United States and Belgium. W R Crom's co-authors include William E. Evans, Mary V. Relling, John H. Rodman, Raymond L. Blakley, Victor M. Santana, Diane Fairclough, Clinton F. Stewart, Ching‐Hon Pui, Cristin Kearns and D. Ayers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Environmental Health Perspectives.

In The Last Decade

W R Crom

23 papers receiving 999 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W R Crom United States 16 408 339 257 255 250 23 1.0k
William M. Hryniuk United States 19 331 0.8× 798 2.4× 360 1.4× 195 0.8× 143 0.6× 28 1.5k
M. L. N. Willoughby United Kingdom 21 522 1.3× 204 0.6× 327 1.3× 362 1.4× 612 2.4× 68 1.6k
G H Reaman United States 13 503 1.2× 160 0.5× 118 0.5× 310 1.2× 378 1.5× 17 915
Eleanor Kane United Kingdom 19 446 1.1× 541 1.6× 398 1.5× 163 0.6× 237 0.9× 49 1.7k
John Lilleyman United Kingdom 17 593 1.5× 123 0.4× 204 0.8× 351 1.4× 286 1.1× 31 1.0k
Peter Johan Moe Norway 22 823 2.0× 209 0.6× 254 1.0× 623 2.4× 387 1.5× 88 1.7k
Roberto Rivera‐Luna Mexico 16 326 0.8× 176 0.5× 129 0.5× 280 1.1× 141 0.6× 67 808
Jean‐Marie Leclerc Canada 18 231 0.6× 320 0.9× 167 0.6× 314 1.2× 139 0.6× 57 1.1k
MV Relling United States 12 884 2.2× 226 0.7× 329 1.3× 725 2.8× 363 1.5× 14 1.5k
Caroline A. Hastings United States 14 422 1.0× 151 0.4× 179 0.7× 474 1.9× 216 0.9× 42 953

Countries citing papers authored by W R Crom

Since Specialization
Citations

This map shows the geographic impact of W R Crom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W R Crom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W R Crom more than expected).

Fields of papers citing papers by W R Crom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W R Crom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W R Crom. The network helps show where W R Crom may publish in the future.

Co-authorship network of co-authors of W R Crom

This figure shows the co-authorship network connecting the top 25 collaborators of W R Crom. A scholar is included among the top collaborators of W R Crom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W R Crom. W R Crom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Houghton, Peter J., et al.. (1997). Probenecid alters topotecan (TPT) systemic and renal disposition. Clinical Pharmacology & Therapeutics. 61(2). 1 indexed citations
2.
Zamboni, William C., W R Crom, Laura C. Bowman, et al.. (1996). Interpatient variability in oral (PO) absorption of topotecan (TPT) in children with relapsed solid tumors.. Clinical Pharmacology & Therapeutics. 59(2). 198–198. 5 indexed citations
3.
Murry, Daryl J., W R Crom, Wilburn E. Reddick, Ravi Bhargava, & William E. Evans. (1995). Liver volume as a determinant of drug clearance in children and adolescents.. Drug Metabolism and Disposition. 23(10). 1110–1116. 96 indexed citations
4.
Crom, W R. (1994). Pharmacokinetics in the child.. Environmental Health Perspectives. 102(suppl 11). 111–117. 49 indexed citations
5.
Relling, Mary V., Diane Fairclough, D. Ayers, et al.. (1994). Patient characteristics associated with high-risk methotrexate concentrations and toxicity.. Journal of Clinical Oncology. 12(8). 1667–1672. 168 indexed citations
6.
Stewart, Clinton F., Sharyn D. Baker, Richard L. Heideman, et al.. (1994). Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.. Journal of Clinical Oncology. 12(9). 1946–1954. 87 indexed citations
7.
Crom, W R, Xiaolong Luo, WM Roberts, et al.. (1994). Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood. 84(4). 1237–1242. 63 indexed citations
8.
Kearns, Christine M., Raymond L. Blakley, Victor M. Santana, & W R Crom. (1994). Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.. PubMed. 54(5). 1235–9. 46 indexed citations
9.
Rodman, John H., Mary V. Relling, Clinton F. Stewart, et al.. (1993). Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.. PubMed. 20(1). 18–29. 33 indexed citations
10.
Santana, Victor M., J Mirro, Cristin Kearns, et al.. (1992). 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.. Journal of Clinical Oncology. 10(3). 364–370. 120 indexed citations
11.
Hurwitz, Craig A., Robert A. Krance, MJ Schell, et al.. (1992). Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.. PubMed. 6 Suppl 2. 39–43. 13 indexed citations
12.
Gregory, R E, Ching‐Hon Pui, & W R Crom. (1991). Raised plasma methotrexate concentrations following intrathecal administration in children with renal dysfunction.. PubMed. 5(11). 999–1003. 8 indexed citations
13.
Mirro, Joseph, et al.. (1989). Targeted Plasma Drug Concentration: A New Therapeutic Approach to Relapsed Nonlymphoblastic Leukemia in Children. Hämatologie und Bluttransfusion. 32. 82–87. 2 indexed citations
14.
Christensen, Michael L., Gaston K. Rivera, W R Crom, M L Hancock, & W. Evans. (1988). Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia.. Journal of Clinical Oncology. 6(5). 797–801. 27 indexed citations
15.
Arbuck, Susan G., et al.. (1986). Etoposide pharmacokinetics in patients with normal and abnormal organ function.. Journal of Clinical Oncology. 4(11). 1690–1695. 79 indexed citations
16.
Crom, W R, et al.. (1983). Cisplatin-induced changes in bleomycin elimination.. PubMed. 67(6). 587–9. 13 indexed citations
17.
Stewart, Clinton F., W R Crom, & Paul Bowman. (1982). Influence of serum concentration on renal clearance of methotrexate in children with acute lymphocytic leukemia. Annals of Pharmacotherapy. 16(6). 2 indexed citations
18.
Cb, Pratt, et al.. (1982). Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.. PubMed. 65(11-12). 1021–6. 31 indexed citations
19.
Evans, William E., et al.. (1980). Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography.. PubMed. 26(13). 1902–4. 47 indexed citations
20.
Evans, W., et al.. (1980). Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography.. Clinical Chemistry. 26(13). 1902–1904. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026